Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645663 | 1.00 | ATM (0.45) | ATMALDH1A1MMP2ANPEPPIK3CD | |
| SCHEMBL20973270 | 0.83 | ATM (0.50) | ATMALDH1A1PIK3CD | |
| SCHEMBL6002159 | 0.83 | ATM (0.50) | ATMALDH1A1PIK3CD | |
| SCHEMBL5065994 | 0.83 | ATM (0.50) | ATMALDH1A1PIK3CD | |
| SCHEMBL2498387 | 0.83 | ATM (0.50) | ATMALDH1A1PIK3CD | |
| SCHEMBL5068787 | 0.83 | ATM (0.50) | ATMALDH1A1PIK3CD | |
| SCHEMBL25258303 | 0.83 | PEPD (0.35) | — | |
| SCHEMBL25259533 | 0.83 | UCHL1 (0.38) | — | |
| SCHEMBL25261946 | 0.83 | PEPD (0.35) | — | |
| SCHEMBL25259584 | 0.83 | UCHL1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| US-7569582-B2 | Aminotropane derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-08-04 | — | — | US | disclosed |
| EP-1773829-B1 | AMINO-TROPANE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-12-17 | — | — | EP | disclosed |
| US-20070191361-A1 | AMINOTROPANE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | disclosed |
| EP-1773829-A1 | AMINO-TROPANE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006021657-A1 | AMINO-TROPANE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191361-A1 | AMINOTROPANE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MC5R, TAAR5, MC4R | ATM 1430/4885ALDH1A1 460/4885MMP2 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.